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3 of 16 patients with extensive psoriasis have been 
completely cleared of skin lesions within 2-3 weeks of 
continuous peritoneal dialysis, and 2 of them up to 2 mo 
after termination of therapy. In 5 cases there was a great 
improvement of psoriatic lesions and in 6 remaining 
cases only a slight improvement was found. The remis-
sion of psoriasis was correlated with extremely high 
polymorphonuclear leukocyte depletion through the 
peritoneal cavity in a short time. 
Neutral serine proteinases were extracted from poly-
morphonuclear leukocytes and quantitated. The quan-
tity of enzymes in the cells recovered from peritoneal 
dialysates was found to decrease with duration of treat-
ment, and it was 2- 5 times lower than amounts of neutral 
proteinases extracted from peripheral blood polymor-
phonuclear leukocytes of psoriatics and normals. 
The enzyme content per polymorphonuclear leukocyte 
of patients with active psoriasis was significantly higher 
(2-fold) than that in inactive psoriasis and in normal 
controls. 
Proteinase activity was ·also found in the sera of pso-
riatics and normals, as well as in the peritoneal dialy-
sates. However, this activity appeared to be about 30- 50 
times lower than serum inhibitory activity against n eu-
tral proteinases . The concentration of neutral proteinase 
inhibitors .in 5 of 17 sera of patients with psoriasis was 
significantly lower than that in normal sera. 
These data indicate that the depletion of activated 
PMNL with increased amounts of neutral proteinases 
may account for the beneficial effect of peritoneal di-
alysis in the clearing of psoriatic lesions. 
The polymorphonuclear leukocytes (PMNL) seem to play an 
important role in the pathogenesis of psoriasis. PMNL form so 
called Munro's microabscesses in t he stratum corneum (SC) of 
psoriatic lesions. It has been shown that psoriatic scales contain 
a chemotactic factor for leukocytes, presumably the products 
of activation of complement system [1,2). 
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Abbreviations: 
BANE: N -tertiary-butylocarboxyl-L-alanine p-nitrophenyl ester 
BTEE: N-benzoyl-L-tyrosine ethyl ester 
DFP: di-isopropyl flu orophosphate 
PBS: phosphate buffered saline 
PCMB: p-chloromercuribenzoate 
PMNL: polymorphonuclear leukocyte 
PMSF: phenlymethylsulfonyl fluoride 
pu: proteolytic units 
SBTI: soybean trypsin inhibitor; type I-S 
TAME: p-toluenosulfonyl-L-arginine methyl ester 
TCA: trichloroacetic acid 
Complement cleavage products could be generated by neutral 
serine proteinases in the epidermis of psoriatic plaques [3,4], or 
presumed formation of immune complex in the SC of psoriatic 
lesions due to the binding of natmal anti-SC autoantibodies 
[5). 
Peripheral blood PMNL of patients with psoriasis were found 
to have both an increased adherence [6) and chemotactic activ-
ity toward nospecific chemoattractant such as Shigella flexneri 
lipopolisaccharide activated serum [7], a reduced spontaneous 
motility [8], as well as an increased [7] or decreased [9] phag-
ocytic activity as compared to normals. 
Depletion of a large number of PMNL through the peritoneal 
cavity seems to correlate with the clearing of psoriatic lesions 
in patients with extensive psoriasis, treated with a continuous 
peritoneal dialysis [10). These cells contain neu.tral serine pro-
teinases, which, when extracted from PMNL and incubated 
with skin specimens, were capable of inducing morphological 
destruction of the architectme of SC [ll). 
Psoriatic plaques, by comparison with uninvolved skin of 
patients with psoriasis, contained increased amounts of a com-
plement dependent chemotactic factor which appeared to be 
neutral serine proteinase [3,4). It is not completely clear, 
whether this serine proteinase is produced by epidermal cells 
due to their excessive proliferation characteristic for psoriasis, 
as suggested by Lazarus, Yost, and Thomas [ 4], or whether the 
enzyme could be released in the psoriatic epidermis with 
PMNL. 
The purpose of our study was to determine the activity of 
neutral serine proteinase (1) in PMNL recovered either from 
peripheral blood or from peritoneal fluid during continuous 
peritoneal dialysis, and (2) in sera and peritoneal dialysates of 
patients with psoriasis and of normal humans. These enzyme 
activities were conelated with the activity of the disease and 
the concentration of neutral serine proteinase inhibitors, ci.r-
culating in the sera of patients with psoriasis, · 
MATERIALS AND METHODS 
Selection of Patients 
31 patients with psoriasis and 18 healthy volunteers were studied. 
· Continuous peritoneal dialysis was performed in 16 cases with severe 
and extensive psoriatic lesions, involving more than 50% of skin surface, 
which were resistent to conventional treatment with tar, corticosteroid 
oin tments, etc. 4 patients with renal fa ilure served as a control group. 
The classification of patients with psoriasis into 2 groups of disease 
activity in the study of peripheral blood PMNL was based on 2 clinical 
criteria: (1) the character of psoriatic lesions, and (2) the time of 
reappearance of psoriatic lesions. Active psoriasis was defined when 
pin-point lesions, small papules and spontaneous Kiibner phenomenon 
were present up to 1 mo after the reappearance of psoriatic lesions. 
Stationary psoriasis was defined when the psoriat ic plaques lasted for 
more than 3 mo after relapse without any marked peripheral spreading 
and the presence of small papules. 
Dialysis Procedure 
Dialysis was continued for 11-28 consecutive days through an in-
dwelbng Tenckhoff chronic peritoneal catheter, which was placed in 
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the deep pelvic region of the peritoneal cavity. The removal of dialysate, 
and its replacement with 2000 ml of fresh dialysis fluid , was pe1formed 
every 4 hr. Each infusion of a fresh volume of dialysis solution lasted 7-
10 min. The last portion of this solution remained in the peritoneal 
cavity for 8 hr, while the patient slept. The cells suspended in the 
peritoneal fluid were counted in each portion of dialysate and saved for 
further experiments. 92% were PMNL and the viability of recovered 
cells was greater than 95%, as determined by trypan blue exclusion. 
The samples of recovered dialysis fluid were stored at -24 °C. 
Extraction of Cells 
A. Peritoneal fluid PMNL: Leukocytes were washed 2 times in 
Hanks solution and spun down at 200 xg for 10 min. The cells, forming 
a pellet, were resuspended in an equal volume of 0.05 M citrate buffer 
at pH 3.2, and kept overnight at 4°C. The supernate was recovered and 
either brought up to pH 7.2 with 1.0 N and 0.1 N NaOH, or stored 
without neutralization. The small samples of the extract were kept 
frozen at -24°C and thawed immediately before an experiment. l ml of 
the final extract contained soluble material from about 0.3 X 10" PMNL. 
B. Peripheral blood PMNL: 40 ml of peripheral blood was drawn 
into dextran-washed plastic tubes and centrifuged for 10 min at 200 
xg. The cells were resuspended in an equal volume of 2.5% gelatin in 
phosphate buffered saline (PBS) and the erythrocytes were sedimented. 
White blood cell-rich supernate was centrifuged for 10 min at 400 xg, 
and the remaining erythrocytes were lysed with 0.83% ammonium 
chloride for 3 min. The cells were next washed 2 times in PBS, coun ted 
in a hemocytometer, and resuspended in 0.5 mJ of 0.05 M citrate buffer 
(pH 3.2). Recovery of PMNL was about 50%. The final extract of 
peripheral blood PMNL contained soluble materials from 24-100 X lOG 
cells. 
Chemicals 
Enzymes: a-chymotrypsin, bovine pancreas, A grade (Calbiochem); 
trypsin, bovine pancreas, type III (Sigma). 
Substrates 
Casein nach Hammarsten (Merck); N-benzoyi-L-tyrosine ethyl ester 
(BTEE) (Calbiochem), a synthetic substrate for proteinases and chy-
motrypsin-like enzymes; N-tertiary-butylocarboxyl-L-alanine-p-nitro-
phenyl ester (BANE) (Sigma); a synthetic elastase substrate; p-tolueno-
sulfonyl-L-arginine methyl ester (TAME) (Mann), a synthetic trypsin 
substrate. 
Inhibitors 
Soybean trypsin inhibitor; type I-S (SBTI) (Sigma); di-isopropyl 
fluorophosphate (DFP) (BDH) and phenylmethylsulfonyl fluoride 
(PMSF) (Merck), serine inhibitors; p-chloromercuribenzoate (PCMB) 
(BDH), a sulfhydryl group inhibitor. 
Neutral proteinase assay 
Proteolytic activity of neu tral proteinase was determined according 
to the Kunitz method, as modified by Levine, Hatcher, and Lazarus 
[3). Briefly, 100 JLl of 8% heat-denatured casein, 100 JLl of0.2 M phosphate 
buffer (pH 7.45), with an admixture of 0.6 M sodium chloride, 100 JLl of 
0.2 M Tris buffer (pH 8.1) with 5 mM calcium chloride, and 100 JLl of 
PMNL extract in 0.05 M citrate buffer (pH 3.2) were mixed and 400 JLl 
volume sample was incubated at 40°C for l hL 3 ml of cold 5% 
trichloroacetic acid (TCA) was then added and the precipitate was 
centrifuged for 10 min at 8,000 xg. The concentration of TCA-soluble 
pep tides was evaluated due to the presence of aromatic amino acids, by 
absorption measurements of supernates at 280 nm. 
The concentration of PMNL proteinases was calculated in proteo-
lytic units (pu) on the basis of a comparison with the proteolytic 
activity of trypsin against casein. l pu was taken as the increase of 
absorbancy t:..Az•o = 0.230, corresponding to the hydrolysis of casein by 
1 JLg of trypsin under the same experimental conditions when 100 JLl of 
0.001% w /v trypsin was aded, instead of 100 JLl of PMNL extract (see 
Fig 1) . . 
The same jlrocedure was applied to evaluate proteolytic activity of 
100 JLl of sera or peritoneal dialysates. The concentration of neutral 
proteinases of PMNL extracts was taken as the amount of enzyme per 
1 cell (pu/cell), and those of serum or peritoneal dialysates were 
quantitated as pu/ ml. 
Neutral proteinase inhibition assay 
A. Serine reagents: PMNL extract (20.6 pu/ml) was treated with 
DFP doses of 2-5 mg/ml as well as with 1.0 mM PMSF. Preincubation 
with inhibitors was usually done for 30 min at 37°C. 
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FIG 1. Comparison between proteolytic. activity of PMNL extract 
and trypsin against denatured casein. 
B. SH group inactiuator: PCMB was added to PMNL extract (20.6 
pu/ml) up to a final concentration of 10 JLM. 
C. Soybean trypsin inhibitor: A mixture of 100 JLl of PMNL extract 
in 0.05 M phosphate buffer was preincubated for 20 min at 25°C or 40°C 
with increasing amounts of SBTI (2-27 JLg) in aqueous solution, to 
obtain a final concentration of 4-64 JLg/ml. After preincubation the 
residual proteolytic activity was determined by the addition of 100 JLl of 
0.1 M Tris buffer (pH 8.1) with an admixture of 5 mM calcium chloride, 
and 100 JLl of 8% casein in 0.2 M phosphate buffer (pH 7.45), and then 
assayed, as described above. The inhibit ion was the percent decrease in 
proteolytic activity. 
D. Serum proteinase inhibitors: 1-10 JLl of patients serum were added 
to 100 JLl of PMNL extract, of known constant proteolytic activity of 2 
pu, and 100 JLl of 0.2 M phosphate buffer (pH 7.45). The mixture was 
then preincubated at 40°C for 20 min. After preincubation, the residual 
proteolytic activity of PMNL extract against casein was estimated as 
described in the preceding paragraph C. Samples with serum were 
compared to those without serum and results expressed as percent of 
inhibition. Proteinase inhibitors in the dialysates were tested in the 
same manner, i.e., 100 JLI of dialysate was preincubated with PMNL 
extract and Tris buffer. 
Hydrolysis of synthetic peptide substrates 
All esterolytic activity procedures were carried out in thermostated 
teflon stopped cuvettes with a SP500 Unicam spectrophotometer. 
BTEE: PMNL neutral proteinase activity was tested in a mixture of 
about 1 mJ volume, containing 900 JLl of 0.1 M Tris buffer (pH 7.8J with 
the addition of 0.05 M calcium chloride, 50 JLl of 1.0 M potassium 
chloride, 50 JLl of 10 mM BTEE in 50% methanol, and either 50 JLl of 
PMNL extract in citrate buffer of activity of 1.2 pu/ tested previously 
on casein (or 50 JLl of 0.04 J.IM chymotrypsin in 1 mM HCl pH 3.0/1 JLg) . 
Spectrophotometric readings were made at 25°C and 256 nm. The 
enzyme activity was calculated from the increase of absorption versus 
time which was close to linearity during the fust 4 min of the reaction. 
TAME: Trypsin and enzymes extracted from PMNL were assayed, 
according to the test recommended by the Worthington catalogue. 
BANE: PMNL elastase activity was tested in a solution of about 1.3 
mJ volume, containing 1.1 ml Tris-acetate 0.1 M (pH 6.6), 100 JLl of 1 M 
potassium chloride, 10 JLl of 0.2 M calcium ch loride, 20 JLl of 12 mM 
BANE in acetonitrile, and 10-100 JLl of PMNL extract. Spectrophoto-
metric readings were made at 347 nm and 31 °C. The enzyme activity 
was calculated from readings within 2.5 min of start of the reaction. 
The increase in absorption was not linear, in contrast to BTEE ester-
olysis. 
Protein concentration 
Protein content of PMNL extract and dialysate was estimated by 
the ultraviolet absorption method [12). 
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RESULTS 
Recovery of PMNL from Peritoneal Cavity 
The clinical findings in patients with psoriasis were correlated 
with the number of PMNL present in peritoneal fluid during 
the 3-4 weeks of continuous peritoneal dialysis. Complete re-
mission of psoriatic lesions during dialysis was found in 3 
patients who lost more than 100 X 109 cells dming treatment. 
Two additional patients were cleared of their lesions dw·ing the 
2 mo follow-up after termination of the therapy. The patients 
remained free of skin lesions for the 3-10 mo of observation, 
after which new skin lesions appeared. The average number of 
PMNL eliminated through the peritoneal cavity in these 5 
patients (139.4 X 109 ), and in those having a great improvement 
of skin lesions when undergoing dialysis (81.4 X 109 ) was sig-
nificantly higher than the nwnber of PMNL removed from 
patients with only a slight improvement of psoriatic lesions 
(34.6 x 109 ) (Table I) . The following correlation was noted: the 
higher the PMNL loss by dialysis therapy, the better the 
clinical effect of treatment. 
The number of PMNL removed from patients with psoriasis 
dming continuous peritoneal dialysis was 4-90 times greater 
than the number of these cells eliminated through the perito-
neal cavity in the control group of patients with renal insuffi-
ciency. Although continuous peritoneal dialysis was performed 
only for about 1 week in renal failme patients, this group serves 
as a suitable control for the psoriatic patients. Massive loss of 
PMNL via the peritoneal cavity usually started on the 3rd or 
4th day of treatment, and lasted for a fmther 7- 10 days, then 
decreased to the value of daily PMNL loss, seen in patients 
with renal failme. However, in some patients with psoriasis, 
stable but not extensive PMNL depletion, although several-fold 
higher than in the control group, did not result in the clearing 
of psoriatic lesions. 
Characteristic of PMNL Enzymes 
The concentration of proteins in the PMNL extracts varied 
from 1.5 to 4.5 mg/ rnl, as estimated by the ultraviolet absorption 
method. 
PMNL acid extracts were found to hydrolyze denatured 
casein, with an optimum pH of 7 .45. There was a linear increase 
of absorption of hydrolyzates up to llA2so = 0.750 (Fig 1). This 
increase of absorption was shown to be similar for both PMNL 
extract and trypsin in the dose range from 0 to 1 !Lg of trypsin 
in the incubation mixtme that was equal to llA2so = 0.230 (1 
pu). At the higher concentration oftrypsin the absorption curve 
showed loss linearity. 
PMNL extract containing 1.2 pu of enzyme, incubated with 
the synthetic chymotrypsin substrate, BTEE, induced an in-
crease of absorption llA256 = 0.028 per 1 min. The identical 
value of llA256 = 0.028 per 1 min was caused by 1 f.Lg of 
chymotrypsin. It was calculated that PMNL extract proteinases 
could hydrolyze about 30 nm BTEE (pu/ min.) 
Thermal stability of proteolytic (against casein) and estero-
lytic (against BTEE) chymotrypsin-like activity of PMNL ex-
tracts showed the same dependence on pH, 50% inactivation 
occmring at 48°C and pH 3.2, and at 60°C and pH 6.8 (Fig 2). 
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Elastase activity of PMNL extracts was tested by incubating 
extracts with synthetic alanine substrate, BANE. The extracts 
were found to hydrolyze BANE. The increase of absorbancy of 
hydrolysis products at 347.5 nm varied from 0.115 to 0.080 per 
1 min when 0.1 pu of enzymes in 5 f.Ll of PMNL extract was 
added. No constant ratio of hydrolytic activity of chymotrypsin-
like versus elastase-like enzymes in the same extract was deter-
mined. 
The thermal stability of elastase-like activity, tested on 
BANE, showed 50% inactivation at 46°C and pH 3.2, which was 
the same condition necessary for 50% inactivation of chymo-
trypsin-like activity. 
Acid extracts of PMNL were completely inactive towards 
synthetic arginine peptide, TAME, under the conditions estab-
lished for maximal trypsin activity against this substrate. Both 
proteolytic enzymes of chymotrypsin and elastase type in the 
PMNL extract were shown to be inhibited up to 15% of initial 
activity by serine reactants, DFP and PMSF, but not by PCMB. 
The proteolytic activity of PMNL extract was inhibited by a 
natmal plant inhibitor, SBTI (Fig 3). Increasing concentrations, 
up to 30 f.Lg SBTI/rnl, induced a gradual decrease in rate of 
proteolysis to about 53% of initial activity in comparison to 
untreated control samples. Higher SBTI doses did not cause 
further reduction of hydrolysis, and the lowest concentration 
on SBTI inducing maximal inhibition of 4 pu/rnl PMNL extract 
was 34 f.Lg SBTI/rnl. 
The quantity of SBTI inducing 47% inhibition of PMNL 
extract proteinase activity, was about 60 times higher than that 
necessary for specific trypsin inactivation. 
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FrG 2. Thermal stability of neutral proteinases extracted from 
PMNL. 100 f.Ll samples of acid PMNL extract were preincubated at 
different temperatures for 30 min at (a.) pH 3.2, and (b) pH 6.8; and 
tested for proteolytic activity on casein/ solid line/ or estero lytic activity 
on BTEE (dash line). 
TABLE I. Comparison of clinical effect of continuous peritoneal dialysis in patients with psoriasis with PMNL recovery in the subsequent 
weeks of treament 
Clinical effect of dia lysis 
on psoriatic lesions 
L Remission 
2 . Great improvement" 
3. Slight improvement6 
Renal failure 
(5-6 days of dialysis) 
No. of 
cases 
5 
5 
6 
4 
1st 
107.6 ± 98.1 
21.0 ± 9.4 
11.2 ± 4.8 
3.3 ± 1.8 
Absolute number of PMNL X 10-n 
Week of treatment 
2nd 3rd 
24.0 ± 14.1 
39.2 ± 26.2 
14.5 ± 11.9 
6.2 ± 4.3 
20.6 ± 8.7 
10.2 ± 5.5 
" Regression of 60-80% of skin lesions and marked fla ttening of the remaining lesions. 
6 No more than 50% of lesions cleared, only slight flattening and paling. 
Total 
139.4 ± 96.5 
81.4 ± 31.6 
34.6 ± 10.1 
3.3 ± 1.8 
Statistical 
comparison 
with group 3 
(I- test) 
p < 0.05 
p < 0.02 
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0.092 per 100 f.tl); as well as of hydrolizing synthetic substituted 
amino acid esters, BTEE (t.A25(; = 0.007-0.013/ min per 50 f.tl) 
and BANE (t.A347 = 0.012- 0.016/min per 50 j.tl), the above 
showing both chymotrypsin-like and elastase-like activity. 
Casein and BTEE were also shown to be hydrolized by 
peritoneal dialysates, t.A28o = 0.011-0.066 per 100 f.tl and t.A2r.6 
= 0.005-0.011/min per 50 f.tl respectively. 
The elastase activity could not be detected in the peritoneal 
fluid in contrast to its presence in the serum and the PMNL 
acid extract. 
Quantitative Determination of Neutral Serine Proteinase 
A. Peripheral blood PMNL: The amount of neutral serine 
proteinases, extracted from PMNL of patients with psoriasis, 
ranged widely from 5.9 to 29.7 X 10- 8 pu per 1 cell (Table II). 
The mean content of this enzyme, per cell, was found to be 
greater in patients with psoriasis (14.24 x 10- 8 pu/cell) , than in 
normal controls (9.89 X 10-8 pu/cell); but the difference be-
tween these groups was not statistically significant. When the 
results were analyzed according to the activity of the disease, 
patients with active psoriasis showed a marked increase of 
neutral serine proteinases, that could be extracted fro m PMNL 
(19.09 x 10- 8 pu/cell), in contrast to those with stationary 
lesions (8.59 X 10-8 pu/cell) and normals (p < 0.01) . 
B. Peritoneal dialysate PMNL: The mean amount of neutral 
serme proteinases, extracted from the PMNL that were re-
100 
>-
1--
~ 
1--
u 
<( 
g 
1--
~ 
0 
w 50 1--
0 
0: 
CL STI PREINCUBATED WITH 
--' 
<( 
.:J 
0 
t; 6 TRYPS IN AT 25• C 
(iJ 
w ~ PMNL PROTEINASE AT 2s·c 
0: 
;-.: • e PMNL PROTEINASE AT 4o·c 
10 20 30 50 60 
ST I ( ug / ml I 
FIG 3. Inhibition of PMNL neutral proteinase- and trypsin-induced 
hydrolysis of casein by soya-bean trypsin inhibitor (SBTI). 
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covered in dialysates dming the continuous peritoneal dialysis, 
was about 2-3 times lower (4.99 X 10- 8 pu/cell) than the mean 
amount of enzyme in peripheral blood PMNL (14.24 x 10- 8 pu/ 
cell) in patients with psoriasis, although it varied markedly 
from 1.03 to 13.01 x 10- 8 pu per cell (Table II and III). 
The neutral proteinase activity in t he peritoneal PMNL was 
found to decrease gradually in the subsequent days of peritoneal 
dialysis (Table III). The content of enzyme, recovered from 1 
PMNL within 1-2 and/or 3- 6 days of treatment, was signifi-
cantly greater than that in cells obtained 7 days or more after 
initiation of dialysis (p < 0.05). 
The method of acid extraction of peritoneal PMNL with 0.05 
M citrate buffer at pH 3.2 leads to the recovery of about half 
(45.5%) the neutral serine proteinases of the cells in comparison 
with the quantity of enzymes relesed by freezing-thawing of 
PMNL. 
C. Serum and peritoneal dialysate: The quantity of neutral 
proteinase was determined in the sera of 15 patients with 
psoriasis and of 8 normals, as well as in the dialysates of 
psoriatics treated by peritoneal dialysis (Table IV). There was 
no difference between the mean proteolyt ic activity of psoriatic 
serum (1.99 pu/ml) and normal serum (1.56 pu/ml). Only 2 of 
15 patients with psoriasis were found to have significantly 
higher activity of serum neutral serine proteinases than the 
normal controls. The activity of this enzyme in the peritoneal 
dialysates (1.39 pu/ml) did not exce.ed its mean activity in 
psoriatic serum, despite the high concentration of PMNL sus-
pended in dialysates, up to 23.4 X 106 cells per ml (Table IV). 
Unbound serum inhibitors of neutral serine proteinase. The 
psoriatic and normal sera were found to inhibit the activity of 
neutral serine proteinases extracted from peritoneal or periph-
eral blood PMNL (Table V and Fig 4). Enzyme activity de-
creased approximately linearly with increasing volume of nor-
mal serum, added in the range of 1- 10 J.!l, up to about 40% of 
the initial proteolytic activity, in comparison with control sam-
ples without serum. A similar relationship was determined 
between the mean inhibition induced by increasing doses of 
serum and its volume in 17 patients with psoriasis. However, 
sera of 5 patients with severe longlasting psoriatic lesions were 
found to have markedly lower inhibitory activity for PMNL 
neutral proteinases than normal serum, especially when added 
in doses of 1-5 f.tl (Fig 4). In these patients, a significantly 
greater volume of serum was necessary to produce 25% inhibi-
tion of proteolytic activity of PMNL extract (Table V) . The 
mean volume of psoriatic serum (4.63 Ill) and of normal serum 
(3.76 f.tl), which caused 25% inhibition of neutral proteinase 
activity, did not differ significantly. Also, there was no difference 
between the serum volume inducing 50% inhibit ion of both 
psoriatics and normals (6.92f.tl and 7.74 J.!l, respectively). 
TABLE ll. Quantity of neutral proteinases in peripheral blood PMNL 
Peripheral blood 
PMNL 
Psoriasis 
Active lesions 
Stationary lesions 
Normal 
No. of 
cases Mean 
13 14.24 
7 19.09 
6 8.59 " 
8 9.89 
Neutral proteinase per I cell (pu x JO') 
t-test 
SD Range 
7.26 5.9-29.7 NS 
6.07 10.8-29.7 p < 0.01 
3.33 5.9-14.7 NS 
4.82 3.6-17.6 
TABLE III. Quantity of neutral proteinases in peritoneal PMNL depleted during dialysis in patients with psoriasis 
Peri toneal 
PMNL . 
recovered in 
dialysates 
within 
1. 1-2 day 
2. 3-6 day 
3. 7-14 day 
Total 
No. of 
cases Mean 
3 9.17 
7 5.32 
5 2.02 
15 4.99 
Neutral prote inase per I cell (pu x IO") Statistical 
comparison 
SD Range wi th group 3 (I.-test) 
5.47 2.9-13.01 p < 0.05 
2.90 1.53-9.02 p < 0.05 
1.09 1.03-3.60 
3.89 1.03-13.01 
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TABLE IV. Proteolytic activity of serum and peritoneal dialysate against casein in patients with psoriasis and normal controls 
Body Quantity of neutral proteinase (pu/ ml) Statistical Group fluid so Range comparison Mean (t-test) 
Psoriasis (15) Serum 1.99 0.99 0.95-4.00" NS 
Dialysate 1.39 0.78 0.48-2.86 
Normal (8) Serum 1.56 0.78 0.86-2.95 
" 2 of 15 patients were found to have the quantity of neutral proteinase in serum higher more than 2 SD above the mean of that of normal 
controls. 
TABLE V. Inhibition of neutral proteinase of PMNL extmct by serum of patients with psoriasis and normal controls 
Serum volume (JLl) 
Statistical 
Psoriasis ( 17) Normal (9) %Patients" comparison (/-test) 
Mean so Range Mean so Range 
25% inhibition 4.63 1.5 1.2-7.5 3.76 0.8 2.5-5.1 29.4 NS 
50% inhibition 6.92 1.9 3.5-10.0 7.74 2.2 4.3-9.3 NS 
" In whom the volume of serum necessary for 25% or 50% inhibition of enzyme activi ty was greater than the mean volume (±2 SD) of serum 
in control group. 
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FIG 4. Inhibi tion of PMNL neutral proteinase activi ty against casein 
in the PMNL acid extract by increasing doses of serum of 17 patients 
with psoriasis and 9 normal volunteers. Patient J .F. is an example of 
decreased serum inhibi tory activity for PMNL neutral proteinases that 
has been found in 5 of 17 psoriatics. 
It was calculated that 1 ml of serum of normal humans and 
of the majority of patients with psoriasis contains factors ca-
pable of inhibiting 50-70 pu of neutral serine proteinases. This 
value is approximately 30-fold greater than the activity of 
neutral serine proteinases, circulating in the human serum 
(Table IV). 
Peritoneal dialysates were found to have no inhibitors for 
neutral serine proteinases isolated from PMNL extracts. 
DISCUSSION 
Continuous peritoneal dialysis was found to be of limited 
value for treatment of widespread psoriasis. Only 5 of 16 pa-
tients were cleared of their psoriat ic lesions during dialysis, or 
within 2 mo after termination of therapy. 
The beneficial clinical effect of peritoneal dialysis seems to 
be related to the depletion of the high number of PMNL, 
exceeding several times the pool of circulating PMNL. Com-
p lete remission during treatment was produced in patients with 
psoriasis, showing within 4-6 days extremely high PMNL loss, 
(more than 100 X 10~ cells), which had struted in the frrst week 
of dialysis . 
Our interpretation of the role of PMNL elimination, as fun-
damental in the healing of psoriatic lesions, is still hypothetical. 
In contrast, the removal of the soluble "psoriatogeneic" factor, 
as suggested by some authors to be responsible for beneficial 
effect of dialyses [13-15], seems to be unlikely, taking into 
consideration the duration of dialysis (3- 4 weeks). In a period 
of time, such as 3- 4 weeks, peritoneal dialysis should remove 
dialyzable materials accumulated in excess in the body fluids, 
or immune complexes of importance for pathogenesis of the 
disease, if any, to the same extent in all patients. However, 
dialysis was fully successful in only 5 of them. 
The number of PMNL, recovered from the peritoneal cavity, 
permitted the extraction of an amount of proteolytic enzymes 
that was sufficient for their identification. These enzymes, 
extracted from peritoneal and/or peripheral blood PMNL, were 
found to have the characteristic of neutral serine proteinases of 
both chymotrypsin-like and elastase-like activity. They could 
digest at pH 7.5 casein and synthetic substrates for both chy-
motrypsin and elastase, BTEE and BANE respectively, but not 
synthetic trypsin substrate, TAME. These activities could be 
almost completely (85%), inhibited by serine blockers, DFP and 
PMSF; partially inhibited by human serum and by high con-
centrations of soya-bean specific trypsin inhibitor, but not by 
SH group inactivator, PCMB. 
Thus, the method of acid extraction appeared to be satisfac-
tory for separation of PMNL serine proteinases operating at 
neutral pH, which, being released from the PMNL, could act 
against tissue. Thermal stability curves at pH 3.2 and 6.8 
confirm the similarity of these enzymes to chymotrypsin iso-
lated from PMNL and pmified by Schmidt and Havemann 
[16), despite admixture of other leukocyte proteinases. 
Om data indicate that we ru·e dealing with proteolytic en-
zymes which were cru·efully characterized by Stru·key and Bar-
rett [17,18] and others [16,19,20), and which ru·e known as 
cathepsin G and PMNL elastase. 
A quantitative assay for the determination of neutral serine 
proteinases in the PMNL extracts and body fluids was devel-
oped. The content of neutral proteinases in the peripheral blood 
PMNL in patients with active psoriasis was significantly greater 
than in patients with stationru·y psoriasis and in normal con-
trols. This might indicate that circulat ing PMNL could be 
stimulated in vivo by an as yet undefined factor. Determination 
of enzym e content may be a better index of cell activation in 
psoriasis than excessive chemoattraction of PMNL to chemo-
tactic factors (7]. PMNL stimulated in vivo might not respond 
to the second stimulus acting in in vitro conditions, therefore 
the measurement of the quantity of enzymes in the cells seems 
to be a more objective method. 
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The quantity of neutral proteinases, extracted from perito-
neal PMNL, was about 2-5 times lower in comparison to that 
of peripheral blood PMNL. This finding may be the result of 
the release of enzyme from cells into the peritoneal fluid. The 
content of proteolytic enzymes in the cells was found to decrease 
with duration of treatment. In the first 2 days of dialysis, PMNL 
contained a significantly greater amount of neutral proteinases 
than after 6 or more days of therapy. This indicates that 
activated PMNL are replaced by other nonstimulated cells with 
normal or even reduced content of proteolytic enzymes. 
Neutral serine proteinases could be identified in human se-
rum of both normals and psoriatics, as well as in peritoneal 
fluid recovered from patients undergoing dialysis, even in the 
absence of suspended PMNL. It should be noted that proteo-
lytic activity of human serum against casein, BTEE, and BANE 
was measured, despite the presence of unbound serum inhibi-
tors to neutral serine proteinases capable of inactivating as 
much as a 50-fold higher amount of these enzymes in the 
PMNL extract. 10 p.l of serum of proteolytic activity of about 
0.02 pu against casein was capable of inhibiting about 1.2 pu of 
neutral proteinases of acid PMNL extract. This might indicate 
that unbound neutral proteinases are present in the human 
serum, or the enzymes are in active equilibrium (complex) with 
their inhibitors and could react also with a new substrate added 
to the serum. 
The reduced inhibitory activity of psoriatic serum for prote-
olysis induced by neutral serine proteinases in 5 of 17 patients 
with psoriasis could be interpreted as an exhaustion of serum 
inhibitors during longlasting disease process, or it may indicate 
some defect of the inhibition system, involving inhibitors of 
high specificity towards distinct neutral serine proteinases. Un-
fortunately, in om experimental conditions, the nonspecific 
effect of all serum inhibitors [21] on a number of proteolytic 
enzymes of PMNL acting in a neutral pH was studied. It is 
possible that there is some deficiency of neutral proteinase 
specific tissue inhibitor in psoriasis, which could be determined 
with a more sensitive assay [22]. 
The neutral proteinases, found in higher concentration in 
psoriatic skirt in comparison to uninvolved skin in psoriasis 
[ 4], could be, at least partly, of PMNL origin, after release to 
the epidermis from leukocytes chemoattracted to psoriatic le-
sion. Furthermore, stratum corneum was found to be a sub-
strate for proteolytic activity of this enzyme [11], which could 
presumably induce the in vivo antigenic conversion of SC, 
allowing binding of universal circulating anti-SC autoantibodies 
in psoriatic scales. 
The reason for the immune complex formation in the initial 
psoriatic lesions is unknown; however, the enzymes of PMNL 
infiltrating the skin could be of significance. Deposition of 
immune complexes could be the second step event that may 
activate chemoattractive component of complement in, already 
developed, psoriatic lesions and could induce the attraction of 
a new portion of PMNL releasing neutral proteinases to the 
epidermis. This subsequently, could provoke antigenic changes 
in the vicinity of the initial psoriatic lesions and the binding of 
a new portion of anti-SC autoantibodies. 
Elimination of activated PMNL, with increased content of 
neutral serine proteinases, through the peritoneal cavity, and 
replacement of these cells with normal unstimulated PMNL 
from extravascular pool could break up such a vicious circle. 
The maintenance of the disease in the self-perpetuation mech-
anism -could be limited, due to reduced penetration of PMNL 
to the psori?tic lesions, during peritoneal dialysis. This, there-
fore, seems to be responsible for its beneficial effect in the 
clearing of psoriatic lesions. 
The clearing of psoriatic lesions by hemodialysis [13,15,23,24] 
could be also explained by a similar mechanism inducing the 
depletion of PMNL. It is known that PMNL adhere to the 
plastic tubes during this procedw-e, while the procedw-e acti-
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vates complement causing the aggregation of PMNL in the 
lungs [25]. 
Although the role of PMNL and their proteolytic enzymes 
seems to be essential in the pathogenesis of the disease, the 
natw-e of the factor responsible for PMNL activation in vivo in 
active psoriasis, as well as the primary event in the development 
of initial psoriatic lesion, remains to be elucidated. 
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